Pfizer FY2027 EPS Estimate Increased by Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Stock analysts at Erste Group Bank increased their FY2027 earnings per share estimates for Pfizer in a research note issued to investors on Monday, July 27th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings per share of $2.86 for the year, up from their previous forecast of $2.84. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm posted $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Other equities analysts have also issued research reports about the stock. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Morgan Stanley boosted their price target on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Trading Up 2.3%

Shares of PFE stock opened at $25.25 on Wednesday. The firm’s 50-day simple moving average is $25.09 and its 200-day simple moving average is $26.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75. The firm has a market cap of $143.88 billion, a P/E ratio of 19.27 and a beta of 0.35.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is presently 131.30%.

Institutional Trading of Pfizer

Large investors have recently added to or reduced their stakes in the stock. Cary Street Partners Financial LLC grew its stake in shares of Pfizer by 10.2% in the second quarter. Cary Street Partners Financial LLC now owns 153,898 shares of the biopharmaceutical company’s stock valued at $3,706,000 after buying an additional 14,274 shares in the last quarter. Rosenberg Matthew Hamilton boosted its holdings in Pfizer by 214.3% in the 2nd quarter. Rosenberg Matthew Hamilton now owns 2,722 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 1,856 shares during the period. Advocate Group LLC boosted its holdings in Pfizer by 11.0% in the 2nd quarter. Advocate Group LLC now owns 394,161 shares of the biopharmaceutical company’s stock worth $9,491,000 after acquiring an additional 39,109 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC grew its position in Pfizer by 1.2% in the second quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 805,088 shares of the biopharmaceutical company’s stock valued at $19,387,000 after acquiring an additional 9,806 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its stake in shares of Pfizer by 1.0% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 2,061,791 shares of the biopharmaceutical company’s stock valued at $49,648,000 after purchasing an additional 19,752 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst estimate increase: Erste Group Bank raised its FY2027 EPS estimate for Pfizer to $2.86 from $2.84. Although still below the broader consensus estimate of $2.96, the revision modestly improves the earnings outlook. MarketBeat Pfizer analyst estimate report
• Positive Sentiment: Expectations for a Q2 earnings beat: Preview reports argue that Pfizer has favorable earnings and revenue trends heading into its upcoming quarterly report. This adds near-term support to the stock, particularly after the company exceeded consensus EPS and revenue estimates in its most recent quarter. Pfizer expected to beat earnings estimates
• Positive Sentiment: Pipeline progress: Pfizer completed a Phase 1 study evaluating its ibuzatrelvir tablet formulation. Early-stage completion does not establish efficacy, but it represents continued progress in the company’s antiviral pipeline and may help support longer-term growth hopes. Pfizer ibuzatrelvir Phase 1 study update
• Neutral Sentiment: Value-investor interest: Commentary highlights Pfizer’s low valuation and efforts to reposition around cancer and obesity medicines. The thesis could attract buyers, but execution and the replacement of declining COVID-related revenue remain key uncertainties. Pfizer cancer and obesity reset analysis
• Negative Sentiment: Patent-cliff concerns: Analysts continue to warn that upcoming loss of exclusivity for key products could pressure Pfizer’s revenue and earnings. The stock’s inexpensive valuation may reflect these long-term concerns rather than represent a clear catalyst. Pfizer patent cliff analysis

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.